Showing 2011-2020 of 5808 results for "".
10 Steps to Building Content That Gets Results For Your Practice in 2023
https://practicaldermatology.com/topics/practice-management/10-steps-to-building-content-that-gets-results-for-your-practice-in-2023/23846/Editorial calendars can help organize your marketing content for the year ahead.Aesthetic Advances: New Technology
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/aesthetic-advances-new-technology/20160/Suneel Chilukuri, MD discusses the benefits of some of the new devices he’s using to improve outcomes for his aesthetic patients. He says BTL’s Emface offers him the ability to tighten and tone the facial muscles and lift neck muscles. He describes the benefits of the Sylfirm X RF microneedling systPhysician Spotlight: Steven R. Feldman, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-4/23801/DEI in Dermatology
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/dei-in-dermatology/20143/Dermatology remains one of the least diverse medical specialties, says Jeanine Downie, MD. There have been small steps forward to improve diversity, equity, inclusion, and accessibility in recent years, such as the DREAM initiative from Allergan Aesthetics and skinbetter science. But there is stillRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-37/23755/New Products
https://practicaldermatology.com/columns/new-products/new-products-4/23753/The Current Armamentarium of Topical Therapies to Treat Atopic Dermatitis and Psoriasis
https://practicaldermatology.com/topics/atopic-dermatitis/the-current-armamentarium-of-topical-therapies-to-treat-atopic-dermatitis-and-psoriasis/23748/A review of the alternatives to topical corticosteroids for managing common inflammatory skin diseases.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-36/23740/DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyAncillary Services and Alternative Revenue Streams for Dermatologists
https://practicaldermatology.com/topics/practice-management/ancillary-services-and-alternative-revenue-streams-for-dermatologists/23535/Dermatologists have many opportunities to use their skills beyond patient care.